MiMedx Group (NASDAQ:MDXG) Stock Price Down 6.4% - Should You Sell?

Key Points

• MiMedx shares fell 6.4% to about $3.96 in mid-day trading, with volume down 77% from the stock’s average daily volume.
• Analyst sentiment remains generally positive: six analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and an $8.57 price target.
• The company reported quarterly revenue of $64.36 million, ahead of expectations, while meeting the EPS estimate at a loss of $0.05 per share; institutional investors own 79.15% of the stock.

MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report) shares traded down 6.4% during mid-day trading on Wednesday. The company traded as low as $4.03 and last traded at $3.9610. 300,430 shares traded hands during trading, a decline of 77% from the average daily volume of 1,281,910 shares. The stock had previously closed at $4.23.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MDXG shares. Wall Street Zen upgraded MiMedx Group from a "sell" rating to a "hold" rating in a report on Saturday, August 29th. Seaport Research Partners lowered shares of MiMedx Group to a "neutral" rating in a report on Monday, August 17th. Weiss Ratings upgraded MiMedx Group from a "sell (d)" rating to a "sell (d+)" rating in a report on Thursday, August 27th. Raymond James Financial set a $8.00 price target on shares of MiMedx Group in a report on Monday, August 17th. Finally, Craig Hallum boosted their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the company a "buy" rating in a report on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, MiMedx Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.57.

MiMedx Group Stock Performance

The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The firm has a market cap of $567.74 million, a price-to-earnings ratio of 97.15 and a beta of 1.18. The company has a fifty day moving average price of $4.56 and a two-hundred day moving average price of $4.09.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The firm had revenue of $64.36 million for the quarter, compared to analysts' expectations of $63.46 million. As a group, equities research analysts expect that MiMedx Group, Inc will post -0.10 EPS for the current year.

Institutional Trading of MiMedx Group

A number of large investors have recently added to or reduced their stakes in MDXG. Quadrant Capital Group LLC boosted its holdings in shares of MiMedx Group by 59.8% during the third quarter. Quadrant Capital Group LLC now owns 141,091 shares of the company's stock worth $662,000 after purchasing an additional 52,824 shares during the period. Abel Hall LLC increased its stake in MiMedx Group by 18.0% in the 3rd quarter. Abel Hall LLC now owns 80,573 shares of the company's stock valued at $375,000 after buying an additional 12,284 shares during the period. NorthCrest Asset Manangement LLC acquired a new position in MiMedx Group in the 3rd quarter valued at approximately $63,000. GAMMA Investing LLC increased its stake in MiMedx Group by 2,422.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,719 shares of the company's stock valued at $36,000 after buying an additional 7,413 shares during the period. Finally, Engineers Gate Manager LP lifted its position in MiMedx Group by 88.6% in the 2nd quarter. Engineers Gate Manager LP now owns 38,525 shares of the company's stock worth $148,000 after buying an additional 18,103 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company's portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.